1. Scrip
  2. >>Business

J&J Seeks Command Position In FcRn Space With Momenta Buyout

 
• By Joseph Haas

J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.

Johnson_and_Johnson
J&J will pay $6.5bn to buy out Momenta and its anti-FcRn candidate

Johnson & Johnson is looking to both take a lead position in a burgeoning area of the autoimmune therapy space and bolster its presence in the Boston-area biotech hub with its planned $6.5bn acquisition of Momenta Pharmaceuticals, Inc. Driving the deal announced 19 August is Momenta’s nipocalimab, a fully-human monoclonal antibody targeting neonatal Fc receptor (FcRn), which is in Phase II in multiple autoantibody-driven diseases.

It’s a remarkable turnaround for Momenta, which reduced its workforce in 2018 to de-emphasize biosimilar development and focus instead on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.